A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo.
Zuo D, Chen Y, Cai JP, Yuan HY, Wu JQ, Yin Y, Xie JW, Lin JM, Luo J, Feng Y, Ge LJ, Zhou J, Quinn RJ, Zhao SJ, Tong X, Jin DY, Yuan S, Dai SX, Xu M. A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo. Protein Cell. 2023 01; 14(1):37-50.